Work

Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML)

Year: 2013

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v122.21.1460.1460

Authors: Joseph G. Jurcic, Farhad Ravandi, John M. Pagel, Jae H Park, Dan Douer, Elihu H. Estey, Hagop M Kantarjian, Dragan Cicic, David A. Scheinberg

Institutions: Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, University of Washington, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Actinium Pharmaceuticals (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2520828414

FWCI: 4.024

Cites:

Cited by: 24

Related to: 10